A detailed history of Hsbc Holdings PLC transactions in Maxcyte, Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 32,237 shares of MXCT stock, worth $110,250. This represents 0.0% of its overall portfolio holdings.

Number of Shares
32,237
Previous 18,530 73.97%
Holding current value
$110,250
Previous $72,000 73.61%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.68 - $5.06 $50,441 - $69,357
13,707 Added 73.97%
32,237 $125,000
Q2 2024

Aug 12, 2024

SELL
$3.63 - $5.0 $62,022 - $85,430
-17,086 Reduced 47.97%
18,530 $72,000
Q1 2024

May 15, 2024

BUY
$3.94 - $5.38 $31,839 - $43,475
8,081 Added 29.35%
35,616 $149,000
Q4 2023

Feb 12, 2024

SELL
$2.6 - $5.24 $13,119 - $26,441
-5,046 Reduced 15.49%
27,535 $129,000
Q3 2023

Nov 13, 2023

SELL
$3.02 - $5.1 $23,474 - $39,642
-7,773 Reduced 19.26%
32,581 $101,000
Q2 2023

Aug 11, 2023

SELL
$3.69 - $5.35 $571,488 - $828,581
-154,875 Reduced 79.33%
40,354 $185,000
Q1 2023

May 15, 2023

BUY
$4.03 - $5.89 $331,112 - $483,934
82,162 Added 72.67%
195,229 $966,000
Q4 2022

Feb 14, 2023

SELL
$4.92 - $7.4 $136,038 - $204,610
-27,650 Reduced 19.65%
113,067 $617,000
Q3 2022

Nov 14, 2022

SELL
$4.52 - $6.51 $54,881 - $79,044
-12,142 Reduced 7.94%
140,717 $910,000
Q2 2022

Aug 11, 2022

BUY
$3.59 - $6.81 $6,885 - $13,061
1,918 Added 1.27%
152,859 $708,000
Q1 2022

May 16, 2022

BUY
$5.26 - $10.84 $221,367 - $456,201
42,085 Added 38.66%
150,941 $1.06 Million
Q4 2021

Feb 11, 2022

BUY
$8.87 - $12.94 $50,612 - $73,835
5,706 Added 5.53%
108,856 $1.11 Million
Q3 2021

Nov 12, 2021

BUY
$12.21 - $17.2 $1.26 Million - $1.77 Million
103,150 New
103,150 $1.25 Million

Others Institutions Holding MXCT

About MAXCYTE, INC.


  • Ticker MXCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 101,724,000
  • Market Cap $348M
  • Description
  • MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...
More about MXCT
Track This Portfolio

Track Hsbc Holdings PLC Portfolio

Follow Hsbc Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.